1
|
Lu T, Xia B, Chen G. Advances in polymer-based cell encapsulation and its applications in tissue repair. Biotechnol Prog 2023; 39:e3325. [PMID: 36651921 DOI: 10.1002/btpr.3325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2022] [Revised: 01/06/2023] [Accepted: 01/11/2023] [Indexed: 01/19/2023]
Abstract
Cell microencapsulation is a more widely accepted area of biological encapsulation. In most cases, it involves fixing cells in polymer scaffolds or semi-permeable hydrogel capsules, providing the environment for protecting cells, allowing the exchange of nutrients and oxygen, and protecting cells against the attack of the host immune system by preventing the entry of antibodies and cytotoxic immune cells. Hydrogel encapsulation provides a three-dimensional (3D) environment similar to that experienced in vivo, so it can maintain normal cellular functions to produce tissues similar to those in vivo. Embedded cells can be genetically modified to release specific therapeutic products directly at the target site, thereby eliminating the side effects of systemic treatments. Cellular microcarriers need to meet many extremely high standards regarding their biocompatibility, cytocompatibility, immunoseparation capacity, transport, mechanical, and chemical properties. In this article, we discuss the biopolymer gels used in tissue engineering applications and the brief introduction of cell encapsulation for therapeutic protein production. Also, we review polymer biomaterials and methods for preparing cell microcarriers for biomedical applications. At the same time, in order to improve the application performance of cell microcarriers in vivo, we also summarize the main limitations and improvement strategies of cell encapsulation. Finally, the main applications of polymer cell microcarriers in regenerative medicine are summarized.
Collapse
Affiliation(s)
- Tangfang Lu
- School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, People's Republic of China
| | - Bin Xia
- Engineering Research Center for Waste Oil Recovery Technology and Equipment, Ministry of Education, Chongqing Technology and Business University, Chongqing, People's Republic of China
| | - Guobao Chen
- School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, People's Republic of China
| |
Collapse
|
2
|
Alipour M, Firouzi N, Aghazadeh Z, Samiei M, Montazersaheb S, Khoshfetrat AB, Aghazadeh M. The osteogenic differentiation of human dental pulp stem cells in alginate-gelatin/Nano-hydroxyapatite microcapsules. BMC Biotechnol 2021; 21:6. [PMID: 33430842 PMCID: PMC7802203 DOI: 10.1186/s12896-020-00666-3] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2020] [Accepted: 12/22/2020] [Indexed: 02/06/2023] Open
Abstract
Background Microcapsule is considered as a promising 3D microenvironment for Bone Tissue Engineering (BTE) applications. Microencapsulation of cells in an appropriate scaffold not only protected the cells against excess stress but also promoted cell proliferation and differentiation. Through the current study, we aimed to microcapsulate the human Dental Pulp Stem Cells (hDPSCs) and evaluated the proliferation and osteogenic differentiation of those cells by using MTT assay, qRT-PCR, Alkaline phosphatase, and Alizarine Red S. Results The SEM results revealed that Alg/Gel microcapsules containing nHA showed a rough and more compact surface morphology in comparison with the Alg/Gel microcapsules. Moreover, the microencapsulation by Alg/Gel/nHA could improve cell proliferation and induce osteogenic differentiation. The cells cultured in the Alg/Gel and Alg/Gel/nHA microcapsules showed 1.4-fold and 1.7-fold activity of BMP-2 gene expression more in comparison with the control group after 21 days. The mentioned amounts for the BMP-2 gene were 2.5-fold and 4-fold more expression for the Alg/Gel and Alg/Gel/nHA microcapsules after 28 days. The nHA, addition to hDPSCs-laden Alg/Gel microcapsule, could up-regulate the bone-related gene expressions of osteocalcin, osteonectin, and RUNX-2 during the 21 and 28 days through the culturing period, too. Calcium deposition and ALP activities of the cells were observed in accordance with the proliferation results as well as the gene expression analysis. Conclusion The present study demonstrated that microencapsulation of the hDPSCs inside the Alg/Gel/nHA hydrogel could be a potential approach for regenerative dentistry in the near future. Graphical abstract ![]()
Collapse
Affiliation(s)
- Mahdieh Alipour
- Dental and Periodontal Research Center, Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Nima Firouzi
- Stem Cell and Tissue Engineering Research Laboratory, Sahand University of Technology, Tabriz, Iran
| | - Zahra Aghazadeh
- Stem Cell Research Center and Department of Oral Medicine, Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Mohammad Samiei
- Department of Endodontics, Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Soheila Montazersaheb
- Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Ali Baradar Khoshfetrat
- Stem Cell and Tissue Engineering Research Laboratory, Sahand University of Technology, Tabriz, Iran.
| | - Marziyeh Aghazadeh
- Stem Cell Research Center and Department of Oral Medicine, Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran.
| |
Collapse
|
3
|
Zhang YL, Liu YG, Chen DJ, Yang BL, Liu TT, Li JJ, Wang XQ, Li HTR, Liu ZX. Microencapsulated Schwann cell transplantation inhibits P2X2/3 receptors overexpression in a sciatic nerve injury rat model with neuropathic pain. Neurosci Lett 2018; 676:51-57. [PMID: 29608947 DOI: 10.1016/j.neulet.2018.03.063] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2018] [Revised: 03/29/2018] [Accepted: 03/29/2018] [Indexed: 12/27/2022]
Abstract
Transplantation of Schwann cells (SCs) can promote axonal regeneration and formation of the myelin sheath, reduce inflammation, and promote repair to the damaged nerve. Our previous studies have shown that transplantation of free or micro-encapsulated olfactory ensheathing cells can relieve neuropathic pain. There are no related reports regarding whether the transplantation of micro-encapsulated SCs can alleviate neuropathic pain mediated by P2X2/3 receptors. In the present study, we micro-encapsulated SCs in alginic acid and transplanted them into the region surrounding the injured sciatic nerve in the rat model of chronic constriction injury (CCI). The mechanical withdrawal threshold and thermal withdrawal latency were measured to assess changes in behavior 14 days after the surgery in CCI model rats. Ultrastructural changes in the injured sciatic nerve were assessed using transmission electron microscopy. Co-expression of P2X2/3 receptors with other markers in neurons in the L4-5 dorsal root ganglia (DRG) were assessed using double-label immunofluorescence 14 days after surgery. We determined P2X2/3 mRNA expression and protein level changes in the DRG using quantitative real-time polymerase change reaction technology and Western blotting analysis. We have investigated that the transplantation of micro-encapsulated SCs can alleviate pathological pain caused by P2X2/3 receptor stimulation and explored new methods for the prevention and treatment of neuropathic pain.
Collapse
Affiliation(s)
- Ya-Ling Zhang
- Department of Anatomy, Basic Medical School, Nanchang University, Nanchang, Jiangxi 330006, People's Republic of China
| | - Yi-Guo Liu
- Grade 2013, Medical School of Zhengzhou University, Zhengzhou, Henan 450052, People's Republic of China
| | - De-Jian Chen
- The First Affiliated Hospital of Nanchang University, No.17 Yong Wai Zheng Street, Nanchang, Jiangxi 330006, People's Republic of China
| | - Bao-Lin Yang
- Department of Anatomy, Basic Medical School, Nanchang University, Nanchang, Jiangxi 330006, People's Republic of China
| | - Tao-Tao Liu
- The Fourth Clinical Medical College of Nanchang University, Nanchang, Jiangxi 330006, People's Republic of China
| | - Jia-Juan Li
- The Second Clinical Medical College of Nanchang University, Nanchang, Jiangxi 330006, People's Republic of China
| | - Xiu-Qi Wang
- Queen Mary College of Nanchang University, Nanchang, Jiangxi 330006, People's Republic of China
| | - Hao-Tian Rose Li
- Alexander Mackenzie High School, Richmond Hill, Ontario L4C 3S3, Canada
| | - Zeng-Xu Liu
- Department of Anatomy, Basic Medical School, Nanchang University, Nanchang, Jiangxi 330006, People's Republic of China.
| |
Collapse
|
4
|
Zhu H, Xi Z, Yang S, Zhang Y, Wang H, Guo H, Zhang Y, Chen D, Guo D. Responses of Free Radicals to Subcutaneous Implantation of Alginate-Chitosan-Alginate (ACA) Microcapsules in Mice. Int J Artif Organs 2018; 32:224-31. [DOI: 10.1177/039139880903200406] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The objective of this study was to characterize the levels of free radicals in serum and antioxidase activity after microcapsules were implanted into the subcutaneous space of mice. Cell viability was evaluated using AO/EB staining. Serum free radicals, malondialdehyde and superoxide dismutase levels were evaluated by colorimetry analysis. The mice were divided into three groups: saline injection group (n=15), empty microcapsules injected group (n=21), encapsulated cells injected group (n=21). Cell viability and serum analysis were executed at 1, 4 and 7 days post-implantation. Hydrogen peroxide and malondialdehyde levels initially increased in the recipients of the empty microcapsules, before decreasing to the basal level. However, in mice receiving the encapsulated cells, the levels were higher at the end of study. Nitric oxide and superoxide dismutase increased after the implantation of microcapsules with or without the BHK-21 cells, but were not changed in response to the saline injection. The viability of the encapsulated cells was high in vivo, although some microcapsules had broken by 7 days post-implantation. These results suggest that nitric oxide plays a role in the specific response to microcapsules. The levels of free radicals rapidly increased immediately following microcapsule transplantation, but they caused only slight cellular damage before the microencapsulated cells were exposed.
Collapse
Affiliation(s)
- Haibao Zhu
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan - China
| | - Zhaofang Xi
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan - China
| | - Shijin Yang
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan - China
| | - Yanhong Zhang
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan - China
| | - Hong Wang
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan - China
| | - Huitian Guo
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan - China
| | - Yao Zhang
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan - China
| | - Dachi Chen
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan - China
| | - Dingzong Guo
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan - China
| |
Collapse
|
5
|
Zhang YL, Chen DJ, Yang BL, Liu TT, Li JJ, Wang XQ, Xue GY, Liu ZX. Microencapsulated Schwann cell transplantation inhibits P2X3 receptor expression in dorsal root ganglia and neuropathic pain. Neural Regen Res 2018; 13:1961-1967. [PMID: 30233070 PMCID: PMC6183027 DOI: 10.4103/1673-5374.238715] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Schwann cell transplantation is a promising method to promote neural repair, and can be used for peripheral nerve protection and myelination. Microcapsule technology largely mitigates immune rejection of transplanted cells. We previously showed that microencapsulated olfactory ensheathing cells can reduce neuropathic pain and we hypothesized that microencapsulated Schwann cells can also inhibit neuropathic pain. Rat Schwann cells were cultured by subculture and then microencapsulated and were tested using a rat chronic constriction injury (CCI) neuropathic pain model. CCI rats were treated with Schwann cells or microencapsulated Schwann cells and were compared with sham and CCI groups. Mechanical withdrawal threshold and thermal withdrawal latency were assessed preoperatively and at 1, 3, 5, 7, 9, 11 and 14 days postoperatively. The expression of P2X3 receptors in L4-5 dorsal root ganglia of the different groups was detected by double-label immunofluorescence on day 14 after surgery. Compared with the chronic constriction injury group, mechanical withdrawal threshold and thermal withdrawal latency were higher, but the expression of P2X3 receptors was remarkably decreased in rats treated with Schwann cells and microencapsulated Schwann cells, especially in the rats transplanted with microencapsulated Schwann cells. The above data show that microencapsulated Schwann cell transplantation inhibits P2X3 receptor expression in L4-5 dorsal root ganglia and neuropathic pain.
Collapse
Affiliation(s)
- Ya-Ling Zhang
- Department of Anatomy, Basic Medical School, Nanchang University, Nanchang, Jiangxi Province, China
| | - De-Jian Chen
- First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China
| | - Bao-Lin Yang
- Department of Anatomy, Basic Medical School, Nanchang University, Nanchang, Jiangxi Province, China
| | - Tao-Tao Liu
- Fourth Clinical Medical College of Nanchang University, Nanchang, Jiangxi Province, China
| | - Jia-Juan Li
- Second Clinical Medical College of Nanchang University, Nanchang, Jiangxi Province, China
| | - Xiu-Qi Wang
- Queen Mary College of Nanchang University, Nanchang, Jiangxi Province, China
| | - Guo-Yong Xue
- Department of Anatomy, Basic Medical School, Nanchang University, Nanchang, Jiangxi Province, China
| | - Zeng-Xu Liu
- Department of Anatomy, Basic Medical School, Nanchang University, Nanchang, Jiangxi Province, China
| |
Collapse
|
6
|
Moustafa T, Girod S, Tortosa F, Li R, Sol JC, Rodriguez F, Bastide R, Lazorthes Y, Sallerin B. Viability and Functionality of Bovine Chromaffin Cells Encapsulated into Alginate-PLL Microcapsules with a Liquefied Inner Core. Cell Transplant 2017; 15:121-33. [PMID: 16719046 DOI: 10.3727/000000006783982106] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Implantation of adrenal medullary bovine chromaffin cells (BCC), which synthesize and secrete a combination of pain-reducing neuroactive compounds including catecholamines and opioid peptides, has been proposed for the treatment of intractable cancer pain. Macro- or microencapsulation of such cells within semi-permeable membranes is expected to protect the transplant from the host's immune system. In the present study, we report the viability and functionality of BCC encapsulated into microcapsules of alginate-poly-L-lysine (PLL) with a liquefied inner core. The experiment was carried out during 44 days. Empty microcapsules were characterized in terms of morphology, permeability, and mechanical resistance. At the same time, the viability and functionality of both encapsulated and nonencapsulated BCC were evaluated in vitro. We obtained viable BCC with excellent functionality: immunocytochemical analysis revealed robust survival of chromaffin cells 30 days after isolation and microencapsulation. HPLC assay showed that encapsulated BCC released catecholamines basally during the time course study. Taken together, these results demonstrate that viable BCC can be successfully encapsulated into alginate-PLL microcapsules with a liquefied inner core.
Collapse
Affiliation(s)
- T Moustafa
- Laboratoire Douleur et Thérapie Cellulaire, Faculté de médecine Rangueil, 133 route de Narbonne, 31 062 Toulouse Cedex, France
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Antinociceptive effect of intrathecal microencapsulated human pheochromocytoma cell in a rat model of bone cancer pain. Int J Mol Sci 2014; 15:12135-48. [PMID: 25007069 PMCID: PMC4139834 DOI: 10.3390/ijms150712135] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2014] [Revised: 06/10/2014] [Accepted: 06/18/2014] [Indexed: 02/01/2023] Open
Abstract
Human pheochromocytoma cells, which are demonstrated to contain and release met-enkephalin and norepinephrine, may be a promising resource for cell therapy in cancer-induced intractable pain. Intrathecal injection of alginate-poly (l) lysine-alginate (APA) microencapsulated human pheochromocytoma cells leads to antinociceptive effect in a rat model of bone cancer pain, and this effect was blocked by opioid antagonist naloxone and alpha 2-adrenergic antagonist rauwolscine. Neurochemical changes of cerebrospinal fluid are in accordance with the analgesic responses. Taken together, these data support that human pheochromocytoma cell implant-induced antinociception was mediated by met-enkephalin and norepinephrine secreted from the cell implants and acting at spinal receptors. Spinal implantation of microencapsulated human pheochromocytoma cells may provide an alternative approach for the therapy of chronic intractable pain.
Collapse
|
8
|
Ambriz-Tututi M, Monjaraz-Fuentes F, Drucker-Colín R. Chromaffin cell transplants: From the lab to the clinic. Life Sci 2012; 91:1243-51. [DOI: 10.1016/j.lfs.2012.10.012] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2012] [Revised: 09/13/2012] [Accepted: 10/05/2012] [Indexed: 11/29/2022]
|
9
|
Ambriz-Tututi M, Sánchez-González V, Drucker-Colín R. Chromaffin cell transplant in spinal cord reduces secondary allodynia induced by formalin in the rat. Role of opioid receptors and α2-adrenoceptors. Eur J Pharmacol 2011; 668:147-54. [DOI: 10.1016/j.ejphar.2011.06.030] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2011] [Revised: 06/07/2011] [Accepted: 06/15/2011] [Indexed: 11/16/2022]
|
10
|
GABAergic pathway in a rat model of chronic neuropathic pain: Modulation after intrathecal transplantation of a human neuronal cell line. Neurosci Res 2011; 69:111-20. [DOI: 10.1016/j.neures.2010.10.006] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2010] [Revised: 09/09/2010] [Accepted: 10/14/2010] [Indexed: 12/30/2022]
|
11
|
Jeon Y. Cell based therapy for the management of chronic pain. Korean J Anesthesiol 2011; 60:3-7. [PMID: 21359073 PMCID: PMC3040428 DOI: 10.4097/kjae.2011.60.1.3] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2010] [Revised: 07/14/2010] [Accepted: 07/14/2010] [Indexed: 01/14/2023] Open
Abstract
The management of chronic pain, particularly neuropathic pain, still has significant unmet needs. In addition to inadequate symptomatic relief, there are concerns about adverse effects and addiction associated with treatments. The transplantation of cells that secrete neuroactive substances with analgesic properties into the central nervous system has only become of practical interest in more recent years, but provides a novel strategy to challenge current approaches in treating chronic pain. This review covers pre-clinical and clinical studies from both allogeneic and xenogeneic sources for management of chronic refractory pain.
Collapse
Affiliation(s)
- Younghoon Jeon
- Department of Anesthesiology and Pain Medicine, School of Dentistry, Kyungpook National University, Daegu, Korea
| |
Collapse
|
12
|
Wu S, Ma C, Li G, Mai M, Wu Y. Intrathecal implantation of microencapsulated PC12 cells reduces cold allodynia in a rat model of neuropathic pain. Artif Organs 2010; 35:294-300. [PMID: 21114677 DOI: 10.1111/j.1525-1594.2010.01059.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The transplantation of cells into the central nervous system provides a constant and replenishable source of analgesic substances for the alleviation of chronic pain. In the present study, PC12 cells were microencapsulated in a semipermeable membrane that protected the cells from the host's immune system. A chronic neuropathic pain model was induced by chronic constriction injury (CCI) of the sciatic nerve in rats. Thirty Sprague-Dawley rats with CCI were divided randomly into two groups: the cell-loaded group received microencapsulated PC12 cells (n = 15) and the control group received empty capsules (n = 15). The microcapsules were implanted into the lumbar subarachnoid space. After implantation, a significant reduction of cold allodynia was observed in the rats of the cell-loaded group at 7, 14, 21, and 28 days compared to the control group with the empty capsules (P < 0.05). Furthermore, the levels of catecholamines and met-enkephalin in the cerebrospinal fluid of rats in the cell-loaded group were higher than the levels in the controls (P < 0.05). These results suggest that intrathecal microencapsulated PC12 cells could be a useful method for chronic neuropathic pain management.
Collapse
Affiliation(s)
- Shaoling Wu
- Pain Treatment Centre of the Department of Rehabilitation Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong Province, China
| | | | | | | | | |
Collapse
|
13
|
Lim GJ, Zare S, Van Dyke M, Atala A. Cell microencapsulation. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2010; 670:126-36. [PMID: 20384223 DOI: 10.1007/978-1-4419-5786-3_11] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
In the past several decades, many attempts have been made to prevent the rejection of transplanted cells by the immune system. Cell encapsulation is primary machinery for cell transplantation and new materials and approaches were developed to encapsulate various types of cells to treat a wide range of diseases. This technology involves placing the transplanted cells within a biocompatible membrane in attempt to isolate the cells from the host immune attack and enhance or prolong their function in vivo. In this chapter, we will review the situation of cell microencapsulation field and discuss its potentials and challenges for cell therapy and regeneration of tissue function.
Collapse
Affiliation(s)
- Grace J Lim
- Department of Urology, Institute for Regenerative Medicine, Wake Forest University, Winston Salem, NC 27157, USA
| | | | | | | |
Collapse
|
14
|
Lv G, Sun Z, Li S, Yu W, Xie Y, Zhang Y, Xie H, Li X, Wang W, Ma X. Permeability changes of the cell-contained microcapsules visualized by confocal laser scanning microscope. J Biomed Mater Res A 2009; 90:773-83. [DOI: 10.1002/jbm.a.32115] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
15
|
Treatment of spinal cord injury by transplantation of cells via cerebrospinal fluid. Neurosci Bull 2009; 24:323-8. [PMID: 18839026 DOI: 10.1007/s12264-008-0618-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
It is very important to probe into the axonal regeneration and functional recovery of central nervous system (CNS) after implantation of cells into cerebrospinal fluid (CSF) for spinal cord injury (SCI). Transplantation of cells via CSF poses great potentials for SCI in clinic. Studies on administration of cells via CSF indicate that the method is safe and convenient. The method is more suitable to treating multiple lesions of the CNS since it does not produce open lesions. However, there are disputes over its promotion effects on axonal regeneration and functional recovery of spinal cord after injury; and some questions, such as the mechanisms of functional recovery of spinal cord, the proper time window of cell transplantation, and cell types of transplantation, still need to be handled. This review summarized the method of cell transplantation via CSF for treatment of SCI.
Collapse
|
16
|
Kim YM, Kwak KH, Lim JO, Baek WY. Reduction of Allodynia by Intrathecal Transplantation of Microencapsulated Porcine Chromaffin Cells. Artif Organs 2009; 33:240-9. [DOI: 10.1111/j.1525-1594.2009.00714.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
Abstract
BACKGROUND Management of chronic pain remains a challenge in spite of numerous drugs that are either approved or still in development. Apart from inadequate relief, there are concerns about adverse effects and addiction. Cell therapy is being explored for relief of pain. OBJECTIVE To address the rationale for cell therapy for treatment of pain and its advantages over conventional pharmaceuticals. The prospects of translation of these techniques from experimental animals to clinical use are discussed. METHODS This review is based on the literature on cell therapy in relation to pain and is confined to experimental work as there are no approved therapies in this category. RESULTS/CONCLUSIONS A number of promising cell therapy technologies have been identified. These provide targeted approaches to delivery of antinociceptive molecules, avoiding subjecting the patient to systemic toxicity of drugs. There has been considerable progress in treating degenerative joint diseases causing pain. Management of neuropathic pain is a challenge and a number of ongoing studies are addressing it. Overall the future of cell therapy for pain is promising.
Collapse
Affiliation(s)
- K K Jain
- Jain PharmaBiotech, Blaesiring 7, CH-4057 Basel, Switzerland.
| |
Collapse
|
18
|
Mukhida K, Mendez I, McLeod M, Kobayashi N, Haughn C, Milne B, Baghbaderani B, Sen A, Behie LA, Hong M. Spinal GABAergic Transplants Attenuate Mechanical Allodynia in a Rat Model of Neuropathic Pain. Stem Cells 2007; 25:2874-85. [PMID: 17702982 DOI: 10.1634/stemcells.2007-0326] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Injury to the spinal cord or peripheral nerves can lead to the development of allodynia due to the loss of inhibitory tone involved in spinal sensory function. The potential of intraspinal transplants of GABAergic cells to restore inhibitory tone and thus decrease pain behaviors in a rat model of neuropathic pain was investigated. Allodynia of the left hind paw was induced in rats by unilateral L5- 6 spinal nerve root ligation. Mechanical sensitivity was assessed using von Frey filaments. Postinjury, transgenic fetal green fluorescent protein mouse GABAergic cells or human neural precursor cells (HNPCs) expanded in suspension bioreactors and differentiated into a GABAergic phenotype were transplanted into the spinal cord. Control rats received undifferentiated HNPCs or cell suspension medium only. Animals that received either fetal mouse GABAergic cell or differentiated GABAergic HNPC intraspinal transplants demonstrated a significant increase in paw withdrawal thresholds at 1 week post-transplantation that was sustained for 6 weeks. Transplanted fetal mouse GABAergic cells demonstrated immunoreactivity for glutamic acid decarboxylase and GABA that colocalized with green fluorescent protein. Intraspinally transplanted differentiated GABAergic HNPCs demonstrated immunoreactivity for GABA and beta-III tubulin. In contrast, intraspinal transplantation of undifferentiated HNPCs, which predominantly differentiated into astrocytes, or cell suspension medium did not affect any behavioral recovery. Intraspinally transplanted GABAergic cells can reduce allodynia in a rat model of neuropathic pain. In addition, HNPCs expanded in a standardized fashion in suspension bioreactors and differentiated into a GABAergic phenotype may be an alternative to fetal cells for cell-based therapies to treat chronic pain syndromes.
Collapse
Affiliation(s)
- Karim Mukhida
- Cell Restoration Laboratory, Department of Anatomy and Neurobiology, Dalhousie University, Halifax, Nova Scotia, Canada
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Jozan S, Aziza J, Châtelin S, Evra C, Courtade-Saïdi M, Parant O, Sol JC, Zhou H, Lazorthes Y. Human fetal chromaffin cells: A potential tool for cell pain therapy. Exp Neurol 2007; 205:525-35. [PMID: 17466976 DOI: 10.1016/j.expneurol.2007.03.020] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2006] [Revised: 01/30/2007] [Accepted: 03/12/2007] [Indexed: 12/25/2022]
Abstract
Transplantation of adrenal medulla cells has been proposed in the treatment of various conditions. Indeed, these cells possess a bipotentiality: neural and neuroendocrine, which could be exploited for brain repair or pain therapy. In a previous study, we characterized these human cells in vitro over 7-10 gestational weeks (GW) [Zhou, H., Aziza, J., Sol, J.C., Courtade-Saidi, M., Chatelin, S., Evra, C., Parant, O., Lazorthes, Y., and Jozan, S., 2006. Cell therapy of pain: Characterization of human fetal chromaffin cells at early adrenal medulla development. Exp. Neurol. 198, 370-381]. We report here our results on the extension to 23 GW. This developmental period can be split into three stages. During the first stage (7-10 GW), we observed in situ that extra-adrenal surrounding cells display the same morphology and phenotype as the intra-adrenal chromaffin cells. We also found that the intra-adrenal chromaffin cells could be committed in vitro towards an adrenergic phenotype using differentiating agents. During the second stage (11 to 15-16 GW), two types of cells (Type 1 and Type 2 cells) were identified morphologically both inside and outside the gland. Interestingly, we noted that the Type 2 cells stem from the Type 1 cells. However, during this developmental period only the intra-adrenal Type 2 cells will evolve towards an adrenergic phenotype. In the third stage (17-23 GW), we observed the ultimate location of the medulla gland. Both the in situ results and the in vitro experiments indicate that particular procedures need to be implemented prior transplantation of chromaffin cells. First, in order to obtain a large number of immature chromaffin cells, they must be isolated from the intra and extra-adrenal gland and should then be committed towards an adrenergic phenotype in vitro for subsequent use in pain therapy. This strategy is under investigation in our laboratory.
Collapse
Affiliation(s)
- Suzanne Jozan
- Laboratory of Pain and Cell Therapy EA 3039, Rangueil Medical School, Histology-Embryology Department, 31062 Toulouse Cedex, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Zhang Y, Wang W, Zhou J, Yu W, Zhang X, Guo X, Ma X. Tumor Anti-angiogenic Gene Therapy with Microencapsulated Recombinant CHO Cells. Ann Biomed Eng 2007; 35:605-14. [PMID: 17277990 DOI: 10.1007/s10439-007-9255-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2006] [Accepted: 01/04/2007] [Indexed: 12/24/2022]
Abstract
Microencapsulation of recombinant cells is a novel promising approach to tumor therapy in which therapeutic protein is sustainable and long-term delivered by microencapsulated cells. The semi-permeable membrane of microcapsule can protect cell from host's immune rejection, increase the chemical stability of therapeutic protein and circumvent the problems of toxicity, limited half-lives and variation in circulating levels. Endostatin, a potent and specific angiogenesis inhibitor, could suppress the growth of primary and metastatic lesions in multiple murine tumor models. In this paper, APA microcapsules with high strength kept intact over 35 days and recombinant CHO cells kept the rapid proliferation viability and the continuous endostatin-expression function. The study of tumor treatment showed that the implantation of microencapsulated recombinant CHO cells decreased the neovascularization of tumor tissue by 59.4% and inhibited the B16 melanoma growth by 77.4%. Twenty days after tumor cell injection, 80% of animals treated with microencapsulated CHO-endo cells were alive compared to only 50% of animals in either control or mock control groups. Therefore, continuous delivery of endostatin from microencapsulated recombinant cells represents a feasible approach to tumor therapy.
Collapse
Affiliation(s)
- Ying Zhang
- Laboratory of Biomedical Material Engineering, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, P.R. China
| | | | | | | | | | | | | |
Collapse
|
21
|
Jeon Y, Kwak K, Kim S, Kim Y, Lim J, Baek W. Intrathecal Implants of Microencapsulated Xenogenic Chromaffin Cells Provide a Long-Term Source of Analgesic Substances. Transplant Proc 2006; 38:3061-5. [PMID: 17112900 DOI: 10.1016/j.transproceed.2006.08.098] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2006] [Indexed: 11/22/2022]
Abstract
Adrenal medullary chromaffin cells secrete several neuroactive substances including catecholamines and opioid peptides that produce analgesic effects in the central nervous system. This study was designed to investigate whether intrathecal microencapsulated chromaffin cells could release analgesic materials producing antiallodynic effects on the chronic neuropathic pain in rats induced by chronic constriction injury (CCI) of the sciatic nerve. Prior to intrathecal implantation, chromaffin cells were encapsulated with alginate and poly-L-lysine to protect them from the host immune system. Behavior tests were performed before CCI, 1 week later, and at 4, 7, 14, 21, 28 days postimplantation. At the end of study, we performed cerebrospinal fluid (CSF) collection and implant retrieval. We observed that intrathecal implantation of encapsulated xenogenic chromaffin cells reduced the mechanical and cold allodynia in a model of neuropathic pain. CSF levels of catecholamines and metenkephalin in the rats that received implants were higher than the controls. In addition, we observed chronic survival of implants. These results suggested that intrathecal microencapsulated chromaffin cells may represent a new approach to chronic neuropathic pain management.
Collapse
Affiliation(s)
- Y Jeon
- Department of Anesthesiology, School of Medicine, Kyungpook National University, Daegu, South Korea
| | | | | | | | | | | |
Collapse
|
22
|
|